TCGA-49-6745-01A-11R-1858-07
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
- age_years
- 82
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.540
- INTERFERON_GAMMA_RESPONSE+0.510
- ALLOGRAFT_REJECTION+0.460
- UV_RESPONSE_DN+0.460
- TGF_BETA_SIGNALING+0.440
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.420
- PROTEIN_SECRETION+0.420
- COMPLEMENT+0.410
- MITOTIC_SPINDLE+0.410
- INFLAMMATORY_RESPONSE+0.400
Top 10 suppressed
- KRAS_SIGNALING_DN-0.270
- PANCREAS_BETA_CELLS-0.260
- SPERMATOGENESIS-0.170
- CHOLESTEROL_HOMEOSTASIS-0.130
- OXIDATIVE_PHOSPHORYLATION-0.110
- BILE_ACID_METABOLISM-0.080
- DNA_REPAIR-0.070
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.070
- UNFOLDED_PROTEIN_RESPONSE+0.000
- XENOBIOTIC_METABOLISM+0.010
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-44-7661-01A-11R-2066-07 | — | cohortA1 | 0.918 |
| 2 | SRR934862 | — | — | 0.909 |
| 3 | TCGA-70-6722-01A-11R-1820-07 | — | cohortSQ1 | 0.905 |
| 4 | TCGA-E7-A97P-01A-11R-A38B-07 | — | — | 0.904 |
| 5 | SRR934816 | — | — | 0.901 |
| 6 | SRR934726 | — | — | 0.899 |
| 7 | 738B9C39-A73F-4BD5-A8D4-3F75B9E14569 | — | — | 0.898 |
| 8 | C6888F62-AE14-4F73-A1B8-2CB81E2809FD | — | — | 0.895 |
| 9 | 2D0A1BA3-EC1D-4B4F-A383-9353C0F4BE85 | — | — | 0.894 |
| 10 | SRR934782 | — | — | 0.892 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 41 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.540 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.510 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.460 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.460 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.440 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.420 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.420 | Remibrutinib | — uncovered |
| COMPLEMENT | 0.410 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.410 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.400 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.390 | Remibrutinib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.390 | Inavolisib | — uncovered |
| APOPTOSIS | 0.380 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.370 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.350 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.350 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.350 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.340 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.320 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.300 | Inavolisib | — uncovered |